Genentech Finds Another Nanoparticle Partner In COUR
Follows January Collaboration With GenEdit
Deal Snapshot: Genentech will pay $40m up front and in the near term, with milestone fees of up to $900m-plus, to use COUR’s tolerogenic nanoparticle treatments in an undisclosed autoimmune disease.
